血液スクリーニングの市場規模：タイプ別、技術別、エンドユーザー別、地域別、範囲および予測

血液スクリーニングの市場規模と予測

血液スクリーニング市場規模は、2023年に27億米ドルと評価され、2024年から2031年の予測期間においてCAGR 8.6%で、2031年には54億米ドルに達すると予測されます。

血液スクリーニングは、感染症、病気、障害を特定するために血液サンプルを分析するプロセスです。HIV、肝炎、その他の血液媒介感染症などのウイルスを特定し、輸血の安全性と治療における早期発見を確保することで、公衆衛生と疾病予防の取り組み全体に貢献します。

血液スクリーニングは、HIV、肝炎、マラリアなどの感染症を検出し、安全な輸血を可能にします。糖尿病や高コレステロールなどの慢性疾患を検出し、がんの早期診断に役立ち、臓器機能をモニターし、多くの病気の危険因子を検出することによって予防医療を促進し、それによって一般公衆衛生と安全性を向上させる。

血液スクリーニングの将来的な応用は、早期の疾患特定を改善し、がんや心臓血管疾患などの疾患に対する個別の治療戦略を可能にします。先進技術は、遺伝子マーカーや感染症を特定する精度を向上させ、より良い予防医療、慢性疾患のモニタリング、より安全な輸血や臓器移植を可能にします。

血液スクリーニング市場力学

血液スクリーニング市場を形成している主な市場力学

主な市場促進要因

献血の増加：

献血の増加：世界の献血と輸血の増加により、効率的な血液スクリーニング法の需要が高まっています。

感染症の有病率の上昇：

HIV、肝炎、ジカウイルスなどの感染症発生率の増加により、厳格な血液スクリーニング・プロトコルが必要とされています。

技術の進歩：

核酸増幅検査（NAT）や次世代シークエンシング（NGS）などの血液スクリーニング技術の革新により、血液検査の精度と効率が向上しています。

政府の取り組み：

血液安全プログラムに対する政府の支援政策と資金援助が市場成長を後押ししています。

国民の意識：

血液安全の重要性に関する一般市民の意識の高まりが市場拡大に寄与しています。

主な課題：

スクリーニングのコスト高：

特に発展途上国では、高度なスクリーニング技術の高コストが導入の障壁となる可能性があります。

規制の厳しさ：

新しいスクリーニング技術に対する厳しい規制要件や長い承認プロセスが市場成長の妨げとなる可能性があります。

低所得地域でのアクセス制限：

低所得地域ではインフラや資源が限られているため、高度な血液スクリーニング法の導入が制限されます。

主要動向：

血液スクリーニングの自動化：

血液スクリーニング・プロセスにおける自動化の統合により、スループットが向上し、手作業によるエラーが減少しています。

人工知能の採用：

血液スクリーニングにおけるデータ解析と解釈にAIと機械学習の導入が進み、診断精度が向上しています。

ポイントオブケア検査：

血液スクリーニングにおけるポイントオブケア検査（POCT）の台頭は、特に遠隔地や十分なサービスを受けていない地域において、迅速かつ信頼性の高い結果を提供しています。

血液スクリーニング市場の地域分析

北米

Verified Market Researchによると、北米が血液スクリーニング市場を独占する見込みです。

この優位性は、輸血需要の高さ、高度なヘルスケアインフラ、Grifols社、Abbott Laboratories社、Bio-Rad Laboratories社などの既存企業の存在によってもたらされます。

さらに、厳しい規制の枠組みや血液の安全性に関する国民の意識が、北米が市場で主導的な地位を占める要因となっています。

アジア太平洋

Verified Market Researchによると、アジア太平洋地域は血液スクリーニング市場で最も急成長している地域です。

アジア太平洋地域は血液スクリーニング市場で最も高い成長率を示すことが期待されています。

ヘルスケアインフラの拡大、献血の増加、感染症の有病率の上昇が市場成長の原動力となっています。

中国、インド、日本のような国々は、血液スクリーニングプロトコルの強化と先進技術の採用に注力しています。

目次

第1章 世界の血液スクリーニング市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の血液スクリーニング市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 血液スクリーニングの世界市場、製品別

• 概要
• 試薬とキット
• 機器
• ソフトウェアとサービス

第6章 血液スクリーニングの世界市場：技術別

• 概要
• 核酸増幅法
• ELISA法
• 迅速検査
• NGS法

第7章 血液スクリーニングの世界市場：エンドユーザー別

• 概要
• 血液銀行
• 病院

第8章 血液スクリーニングの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の血液スクリーニング市場の競合情勢

• 概要
• 企業市場シェア
• ベンダー情勢
• 主な発展戦略

第10章 企業プロファイル

• Grifols
• F. Hoffmann-La Roche
• Abbott Laboratories
• Biomerieux
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers
• Ortho Clinical Diagnostics, Inc.
• Thermo Fisher Scientific, Inc.
• Beckman Coulter
• Becton, Dickinson and Company

第11章 付録

• 関連調査

Blood Screening Market Size And Forecast

The Blood Screening Market size was valued at USD 2.7 Billion in 2023 and is expected to reachUSD 5.4 Billion in 2031, at aCAGR of 8.6% over the forecast period of 2024 to 2031.

Blood screening is the process of analysing blood samples to identify infections, illnesses and disorders. It identifies viruses such as HIV, hepatitis and other blood-borne infections, ensuring blood transfusion safety and early detection in medical treatments and thereby contributing to overall public health and disease prevention initiatives.

Blood screening detects infectious disorders such as HIV, hepatitis and malaria, allowing for safe blood transfusions. It detects chronic disorders like diabetes and high cholesterol, helps with early cancer diagnosis, monitors organ function, and promotes preventative healthcare by detecting risk factors for numerous illnesses, thereby improving general public health and safety.

Future applications of blood screening will improve early disease identification, allowing for individualized treatment strategies for ailments such as cancer and cardiovascular disease. Advanced technology will improve the accuracy with which genetic markers and infections are identified, allowing for better preventive care, chronic condition monitoring and safer blood transfusions and organ transplantations.

Blood Screening Market Dynamics

The key market dynamics that are shaping the Blood Screening Market include:

Key Market Drivers:

Increasing Blood Donations:

A growing number of blood donations and transfusions worldwide is driving the demand for efficient blood screening methods.

Rising Prevalence of Infectious Diseases:

The increasing incidence of infectious diseases such as HIV, hepatitis, and Zika virus necessitates rigorous blood screening protocols.

Technological Advancements:

Innovations in blood screening technologies, including nucleic acid amplification tests (NAT) and next-generation sequencing (NGS), are enhancing the accuracy and efficiency of blood tests.

Government Initiatives:

Supportive government policies and funding for blood safety programs are propelling the market growth.

Public Awareness:

Increased public awareness about the importance of blood safety is contributing to the market expansion.

Key Challenge:

High Costs of Screening:

The high cost of advanced screening technologies can be a barrier for adoption, especially in developing countries.

Regulatory Stringency:

Stringent regulatory requirements and lengthy approval processes for new screening technologies can hinder market growth.

Limited Access in Low-Income Regions:

Limited infrastructure and resources in low-income regions restrict the implementation of advanced blood screening methods.

Key Trends:

Automation in Blood Screening:

The integration of automation in blood screening processes is improving throughput and reducing manual errors.

Adoption of Artificial Intelligence:

AI and machine learning are being increasingly adopted for data analysis and interpretation in blood screening, enhancing diagnostic accuracy.

Point-of-Care Testing:

The rise of point-of-care testing (POCT) for blood screening is providing quick and reliable results, particularly in remote and underserved areas.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Blood Screening Market Regional Analysis

Here is a more detailed regional analysis of the blood screening market:

North America

According to Verified Market Research, North America is expected to dominate the blood screening market.

This dominance is driven by a high demand for blood transfusions, advanced healthcare infrastructure, and the presence of established players like Grifols, Abbott Laboratories, and Bio-Rad Laboratories.

Additionally, stringent regulatory frameworks and public awareness about blood safety contribute to North America's leading position in the market.

Asia Pacific

According to Verified Market Research, Asia Pacific is fastest growing region in blood screening market.

The Asia Pacific region is expected to witness the highest growth rate in the blood screening market.

The expanding healthcare infrastructure, increasing blood donations, and rising prevalence of infectious diseases are driving the market growth.

Countries like China, India, and Japan are focusing on enhancing their blood screening protocols and adopting advanced technologies.

Blood Screening Market Segmentation Analysis

The Blood Screening Market is segmented on the basis of Type, Application and Geography.

Blood Screening Market, By Type

• Reagents & Kits
• Instruments
• Software & Services

Based on Type, the market is segmented into Reagents & Kits, Instruments and Software & Services. Reagents & kits accounted for the largest market share in the global blood screening market. The growing prevalence of infectious diseases and the rising need for safe blood transfusions have driven the demand for high-quality reagents and kits. These products are essential for detecting pathogens in donated blood, ensuring the safety and reliability of blood transfusions. As healthcare facilities and blood banks prioritize accuracy and efficiency in blood screening processes, the adoption of advanced reagents and kits is significantly increasing. This trend reflects the ongoing efforts to enhance blood safety and the overall quality of healthcare services.

Blood Screening Market, By Technology

• Nucleic Acid Testing (NAT)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Rapid Tests
• Western Blotting

Based on Technology, the market is segmented into Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests and Western Blotting. In the Blood Screening Market, Nucleic Acid Testing (NAT) is the dominant technology. NAT is highly favored for its ability to detect viral genetic material at an early stage, significantly reducing the window period during which infections may not be detected by traditional serological methods. This technology ensures a higher level of safety and reliability in blood screening processes, making it crucial for preventing the transmission of infectious diseases through blood transfusions.

Blood Screening Market, By End User

• Blood Banks
• Hospitals
• On the basis of End User, the market is divided into Blood banks and Hospitals. In the blood screening market, blood banks are the dominant end users. Blood banks play a critical role in ensuring the safety and availability of blood for transfusions. They employ rigorous blood screening protocols to detect infectious agents, thereby maintaining the highest standards of blood safety and mitigating the risk of transfusion-transmitted infections.

Blood Screening Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• On the basis of Geography, the Blood Screening Market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest market share in the global blood screening market. The region's dominance is attributed to the well-established healthcare infrastructure, high healthcare expenditure, and the presence of key market players. Moreover, the increasing prevalence of chronic diseases and the rising number of surgical procedures requiring blood transfusions have further boosted the demand for blood screening in North America. The region's strong focus on blood safety, coupled with continuous advancements in screening technologies, ensures the growth and sustainability of the blood screening market.

Key Players

• The "Blood Screening Market" study report will provide valuable insight with an emphasis on the global market, including some of the major players in the industry such as
• Abbott Laboratories, Grifols, Bio-Rad Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Ortho Clinical Diagnostics, Becton Dickinson.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

• Blood Screening Market Recent Developments
• In March 2023, Abbott Laboratories introduced a new high-throughput screening system for detecting infectious diseases in donated blood.
• In August 2023, Roche Diagnostics launched a next-generation sequencing platform for comprehensive blood screening.
• In October 2023, Siemens Healthineers entered into a collaboration with a leading blood bank to implement advanced screening technologies.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD SCREENING MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD SCREENING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD SCREENING MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Reagents & Kits
• 5.3 Instruments
• 5.4 Software & Services

6 GLOBAL BLOOD SCREENING MARKET, BY TECHNOLOGY

• 6.1 Overview
• 6.2 Nucleic Acid Amplification
• 6.3 ELISA
• 6.4 Rapid tests
• 6.5 NGS

7 GLOBAL BLOOD SCREENING MARKET, BY END USER

• 7.1 Overview
• 7.2 Blood Banks
• 7.3 Hospitals

8 GLOBAL BLOOD SCREENING MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL BLOOD SCREENING MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Share
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Grifols
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 F. Hoffmann-La Roche
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Abbott Laboratories
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Biomerieux
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Bio-Rad Laboratories, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Siemens Healthineers
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Ortho Clinical Diagnostics, Inc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Thermo Fisher Scientific, Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Beckman Coulter
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Becton, Dickinson and Company
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research